What are the key takeaways from this Beyond Biotech episode?

Key insights include: **Nonprofit-as-ecosystem-builder model:** Rather than running trials or making drugs, DEBRA Research funds academic grants, takes equity positions as a silent co-investor in biotech companies, builds shared preclinical CRO infrastructure, and funds dedicated clinical trial sites — a multi-pillar approach modeled explicitly on the Cystic Fibrosis Foundation's playbook and replicable for other rare diseases.; **Dedicated clinical site funding:** EB patients require up to three hours daily for bandage changes, making standard health systems inadequate for clinical trial participation. DEBRA Research directly funds specialist physicians and clinical study nurses at expert centers like UMC Groningen to absorb the documentary and personnel burden, enabling sites to attract academic and commercial trial sponsors independently over time.; **Preclinical CRO partnerships for rare disease access:** DEBRA Research established a dedicated academic CRO with Queen Mary University of London to centralize EB-specific assays and patient cell lines, with two to three additional research partners planned. This gives early-stage biotech companies without direct clinic relationships standardized access to scarce patient biosamples and head-to-head compound comparisons.

What did Martin Steiner discuss on Beyond Biotech?

Martin Steiner, Managing Director of DEBRA Research, explains how the German nonprofit bridges early-stage academic EB research and commercial drug development by funding grants, making equity investments in biotech companies, and building dedicated clinical trial infrastructure for a disease affecting roughly 1-in-20,000 people with a life expectancy of 35–40 years. Key topics include: **Nonprofit-as-ecosystem-builder model:** Rather than running trials or making drugs, DEBRA Research funds academic grants, takes equity positions as a silent co-investor in biotech companies, builds shared preclinical CRO infrastructure, and funds dedicated clinical trial sites — a multi-pillar approach modeled explicitly on the Cystic Fibrosis Foundation's playbook and replicable for other rare diseases.; **Dedicated clinical site funding:** EB patients require up to three hours daily for bandage changes, making standard health systems inadequate for clinical trial participation. DEBRA Research directly funds specialist physicians and clinical study nurses at expert centers like UMC Groningen to absorb the documentary and personnel burden, enabling sites to attract academic and commercial trial sponsors independently over time..

How long is this episode of Beyond Biotech?

This episode is 40 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

Beyond Biotech

This nonprofit is building the ecosystem to cure epidermolysis bullosa

July 24, 2026

40 min episode · 2 min read

Martin Steiner

Episode

40 min

Read time

2 min

Topics

Health & Wellness, Relationships, Investing

AI-Generated Summary

Published Jul 24, 2026

Key Takeaways

✓Nonprofit-as-ecosystem-builder model: Rather than running trials or making drugs, DEBRA Research funds academic grants, takes equity positions as a silent co-investor in biotech companies, builds shared preclinical CRO infrastructure, and funds dedicated clinical trial sites — a multi-pillar approach modeled explicitly on the Cystic Fibrosis Foundation's playbook and replicable for other rare diseases.
✓Dedicated clinical site funding: EB patients require up to three hours daily for bandage changes, making standard health systems inadequate for clinical trial participation. DEBRA Research directly funds specialist physicians and clinical study nurses at expert centers like UMC Groningen to absorb the documentary and personnel burden, enabling sites to attract academic and commercial trial sponsors independently over time.
✓Preclinical CRO partnerships for rare disease access: DEBRA Research established a dedicated academic CRO with Queen Mary University of London to centralize EB-specific assays and patient cell lines, with two to three additional research partners planned. This gives early-stage biotech companies without direct clinic relationships standardized access to scarce patient biosamples and head-to-head compound comparisons.
✓Read-through molecules as near-term therapeutic target: DEBRA Research founded a subsidiary, Read On Therapeutics, currently evaluating 20–25 small-molecule compounds that induce read-through of premature stop codons, restoring functional collagen or keratin production. Compounds are sourced from industry, academia, and other nonprofits, then tested head-to-head in dedicated CROs to identify candidates for first-in-human trials before partnering with pharma.
✓Pharma education as deal-making infrastructure: DEBRA Research spent 18 months educating Leo Pharma on EB through patient panels, landscape briefings, and key opinion leader introductions before Leo acquired Replay, a gene therapy company DEBRA had supported. Organizations targeting pharma partnerships should prioritize speaking commercial language — target product profiles, adverse event frameworks — rather than purely scientific or patient-advocacy framing.

What It Covers

Martin Steiner, Managing Director of DEBRA Research, explains how the German nonprofit bridges early-stage academic EB research and commercial drug development by funding grants, making equity investments in biotech companies, and building dedicated clinical trial infrastructure for a disease affecting roughly 1-in-20,000 people with a life expectancy of 35–40 years.

Key Questions Answered

•Nonprofit-as-ecosystem-builder model: Rather than running trials or making drugs, DEBRA Research funds academic grants, takes equity positions as a silent co-investor in biotech companies, builds shared preclinical CRO infrastructure, and funds dedicated clinical trial sites — a multi-pillar approach modeled explicitly on the Cystic Fibrosis Foundation's playbook and replicable for other rare diseases.
•Dedicated clinical site funding: EB patients require up to three hours daily for bandage changes, making standard health systems inadequate for clinical trial participation. DEBRA Research directly funds specialist physicians and clinical study nurses at expert centers like UMC Groningen to absorb the documentary and personnel burden, enabling sites to attract academic and commercial trial sponsors independently over time.
•Preclinical CRO partnerships for rare disease access: DEBRA Research established a dedicated academic CRO with Queen Mary University of London to centralize EB-specific assays and patient cell lines, with two to three additional research partners planned. This gives early-stage biotech companies without direct clinic relationships standardized access to scarce patient biosamples and head-to-head compound comparisons.
•Read-through molecules as near-term therapeutic target: DEBRA Research founded a subsidiary, Read On Therapeutics, currently evaluating 20–25 small-molecule compounds that induce read-through of premature stop codons, restoring functional collagen or keratin production. Compounds are sourced from industry, academia, and other nonprofits, then tested head-to-head in dedicated CROs to identify candidates for first-in-human trials before partnering with pharma.
•Pharma education as deal-making infrastructure: DEBRA Research spent 18 months educating Leo Pharma on EB through patient panels, landscape briefings, and key opinion leader introductions before Leo acquired Replay, a gene therapy company DEBRA had supported. Organizations targeting pharma partnerships should prioritize speaking commercial language — target product profiles, adverse event frameworks — rather than purely scientific or patient-advocacy framing.

Notable Moment

Steiner describes how DEBRA Research is funding development of a self-cooling insole for sneakers alongside gene therapy programs — illustrating that the organization deliberately funds non-drug solutions addressing daily patient burdens, not only curative approaches, as part of its portfolio strategy.

Know someone who'd find this useful?

Episode Transcript

Hello, and welcome to Beyond Biotech, the weekly podcast from La BioTech. I'm Dylan Kysain, and this is episode 207 for the podcast. Epidermolysis bullosa or EB is one of those diseases that stops you in your tracks the moment you understand it. Skin so fragile that the gentlest touch can cause blisters and open wounds, and there's no cure. And even for most of its history, very little serious drug development attention. That's where today's guest comes in. Martin Steiner is managing director of Deborah Research, a nonprofit organization with a single-minded mission, to make EB curable. But Deborah Research isn't a lab. It doesn't run clinical trials or make drugs. What it does is something arguably harder. It builds the ecosystem that makes drug development possible. Funding research, investing in biotech companies, building shared infrastructure, and connecting the right people at the right time. And the results are starting to show they have a growing portfolio of investments, dedicated clinical trial infrastructure, and a seat at the table in deals that are moving the needle for patients that have waited long enough. I hope you enjoy this discussion with Martin Steiner of Deborah Research. Martin, welcome to Beyond Biotech. Hello. Martin, before we jump too much into Deborah Research, can you tell us a little bit about your own background? How did you end up here leading an organization focused on a particular disease? Yes. So I I'm a biologist by training. I have a PhD in microbiology and genetics, and also an MBA. I founded a couple of biotech companies before which I ran as CEO. And in the last fourteen years, I was also a consultant to life science companies, startups, universities, spin offs. And among those, I also consulted, now more than ten years ago with Deborah Research, Deborah Austria, a Austrian patient organization, of, patients living with epidermolysis bullosa. In the course of this last ten years, there was an on and off, consulting activity, on on different matters, mainly on on on research focused topics. And, in 2021, I was asked by Deborah Austria to become, the managing director of Deborah Research. So this is my encounter with with several research. And in the course of this activities, I was more and more attracted by the disease and and by the community. Previously, I have worked in several disease indications from oncology, allergies, infectious diseases. And I am really very much, attracted by this indication and by this communicate community because it is a very close community. It's a very close interaction with patients, with caretakers, and it's it's it's very motivating and encouraging working in this area. For listeners who haven't come across it before, what is Deborah Research, and how does it relate to Deborah Austria that you just mentioned as well? Right. So so Deborah Austria I I start with Deborah Austria. Deborah Austria, is a patient organization, in Austria. It's, there are about 40 national, Deborah's worldwide, in all …

Get the full transcript (5,082 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all Beyond Biotech transcripts →

You just read a 3-minute summary of a 37-minute episode.

Get Beyond Biotech summarized like this every Monday — plus up to 2 more podcasts, free.

Pick Your Podcasts — Free

Keep Reading

How Evox Therapeutics is targeting CNS diseases with exosomes

Sep 4 · 31 min

10% Happier with Dan Harris

The Non-BS Science of Manifestation: How Your Imagination Can Help With Pain, Anxiety, Conflict, and Recovery | Cassi Vieten

Aug 12

BIOSPAIN 2026: partnering, policy, and the rise of Spanish biotech

Aug 28 · 34 min

Cognitive Revolution

Alignment with Awakening: Davidad on Moral Realism, AI Wisdom, & why His p(Doom) is Down to 5%

Jul 12

Books, tools, and gear mentioned in this episode

SignalCast may earn commission on purchases via these links.

company

Leo Pharma
“DEBRA Research spent 18 months educating Leo Pharma on EB through patient panels, landscape briefings, and key opinion leader introductions before Leo acquired Replay.”
Cystic Fibrosis Foundation
“a multi-pillar approach modeled explicitly on the Cystic Fibrosis Foundation's playbook and replicable for other rare diseases.”
Queen Mary University of London
“DEBRA Research established a dedicated academic CRO with Queen Mary University of London to centralize EB-specific assays and patient cell lines.”
UMC Groningen
“DEBRA Research directly funds specialist physicians and clinical study nurses at expert centers like UMC Groningen to absorb the documentary and personnel burden.”
DEBRA Research
“Martin Steiner, Managing Director of DEBRA Research, explains how the German nonprofit bridges early-stage academic EB research and commercial drug development by funding grants, making equity investments in biotech companies, and building dedicated clinical trial infrastructure.”
Replay
“Leo Pharma acquired Replay, a gene therapy company DEBRA had supported.”
Read On Therapeutics
“DEBRA Research founded a subsidiary, Read On Therapeutics, currently evaluating 20–25 small-molecule compounds that induce read-through of premature stop codons.”